Silo Pharma Files Patent for SPC-14 Alzheimer's Treatment Compound.

Silo Pharma has filed a patent application with the USPTO for its neurology drug SPC-14, an intranasal compound for Alzheimer's disease treatment. The patent covers SPC-14's mechanism of action targeting glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms. Early pre-clinical studies have shown efficacy against learned helplessness, perseverative behavior, and hyponeophagia (a measure of anxiety).

Sun Pharma and Moebius Medical have announced the publication of two articles in the journal Osteoarthritis and Cartilage, highlighting MM-II, a novel non-opioid product for treating symptomatic knee osteoarthritis. The publications provide complementary insights into MM-II's clinical efficacy and mechanism of action, underscoring its potential therapeutic value [1].

The first publication presents results from a Phase 2b randomized, double-blind, placebo-controlled trial (NCT04506463), which enrolled 397 patients across the US, Europe, and Asia. Findings demonstrate that a single injection of MM-II provided clinically meaningful pain relief through 26 weeks, with a favorable safety and tolerability profile [1].

The second publication, titled "Empty large liposomes reduce cartilage degeneration in osteoarthritic rats by forming a lubricative coating," details MM-II's unique mechanism of action. The research shows that MM-II forms a lubricative layer over cartilage surfaces, reducing friction and slowing cartilage degeneration [1].

"The data from these publications show that MM-II has the potential to provide durable pain relief for patients," said Prof. Thomas J. Schnitzer, MD, PhD, a rheumatologist and professor of Medicine at Northwestern University and lead author of the clinical trial manuscript. "With limited treatment options, lack of novel treatment approaches, and concerns around opioid use, MM-II may offer a promising alternative to hyaluronic acid and steroid treatments" [1].

Coinciding with these publications, Sun Pharma and Moebius Medical are presenting new data at the OARSI 2025 World Congress on Osteoarthritis, which is taking place this week. Three abstracts were accepted for presentation at the congress, and the companies will also host a satellite symposium exploring MM-II's mechanism of action, clinical data, and planned phase 3 program [1].

Osteoarthritis is one of the most common chronic health conditions and a leading cause of pain and disability among adults. The global market for products used for symptomatic relief of knee osteoarthritis pain, including intra-articular hyaluronic acid and others, is estimated at $2 billion with a 6.5% compound annual growth rate. The US alone accounts for approximately 40% of this market [1].

Moebius Medical is a clinical-stage biotechnology company developing novel pain relief treatments for osteoarthritis. The company was founded in 2008 within the RAD Biomed Accelerator to develop products based on a patent-protected technology exclusively licensed from Yissum, the Hebrew University Technology Transfer Company; T3, the Technology Transfer arm of the Technion Institute; and by Hadasit, the Technology Transfer company of Hadassah Medical Center. In 2016, Moebius formed a joint collaboration with Sun Pharma in which Moebius is responsible for conducting certain preclinical studies and for product development and manufacturing through the end of Phase 2 studies, at which point Sun has the option to assume further product development and commercialization [1].

Sun Pharma is the world's leading specialty generics company with a presence in specialty, generics, and consumer healthcare products. It is the largest pharmaceutical company in India and a leading generic company in the US as well as global emerging markets. Sun Pharma's high-growth global specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales [1].

References:
[1] https://www.biospace.com/press-releases/sun-pharma-and-moebius-medical-announce-dual-publications-on-mm-iis-phase-2b-clinical-trial-results-and-mechanism-of-action-in-osteoarthritis-and-cartilage